Iris T. Chan
Children's Hospital of Philadelphia(US)The London College(GB)Imperial College London(GB)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Advanced Breast Cancer Therapies, Estrogen and related hormone effects, PI3K/AKT/mTOR signaling in cancer, Acute Myeloid Leukemia Research
Most-Cited Works
- → Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study(2014)294 cited
- → Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant(2016)292 cited
- → Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease(2004)261 cited
- → Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)(2012)247 cited
- → Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors(2019)88 cited
- → A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors(2016)83 cited